Post-marketing Surveillance Study of Adalimumab (Humira®) for Non-infectious Intermediate, Posterior, or Panuveitis Patients

AbbVie

Status: Completed

Conditions: Non-infectious Intermediate, Posterior and Panuveitis

Study type: Observational

Funder types: Industry

Identifiers

NCT03339102

P17-176

Details and patient eligibility

About

The objective of this study is to evaluate the safety and effectiveness of Humira® (Adalimumab) for the treatment of non-infectious intermediate, posterior, or panuveitis patients under a routine treatment practice.

Enrollment: 158 patients

Sex: All

Ages: 19 to 99 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patient has been diagnosed with Non-infectious intermediate, posterior and pan-uveitis
• Patients voluntarily signed a patient authorization & informed consent form.
• Decision on the treatment with Humira® was made prior to any decision to approach the patient to participate in this study.
• Humira® treatment is indicated as per local Summary of Product Characteristics (SmPC) and professional and/or reimbursement guidelines.

Exclusion criteria

• A patient who are contraindications to originator adalimumab (Humira®) as listed on the approved Korean label.
• A patient who is participating on other interventional clinical trials
• Prior treatment with Humira®, including current course of Humira® started prior to baseline visit assessments.

Trial design

158 participants in 1 patient group

Participants who received Humira®

Description:

Non-infectious intermediate, posterior, or panuveitis patients who received Humira®